The Therapeutic Potential of Botulinum Toxin

Dermatologic Surgery

Volumn 30, Issue 3, 2004, Pages 452-455

  Klein, Arnold William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; SUBSTANCE P;

ADULT; ANALGESIA; ARTICLE; CASE REPORT; DIZZINESS; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MUSCLE CONTRACTION; NEUROPATHIC PAIN; NEUROPATHY; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; SKIN TINGLING;

ADULT; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEURALGIA; NEUROMUSCULAR AGENTS; PAIN;

EID: 1942439990     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2004.30118.x     Document Type: Article

References (44)

1. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997;4(Suppl 2):S71-S73.
2. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38:468-71.
3. Carruthers A, Langtry JA, Carruthers J, Robinson G. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 1999;39:662-5.
4. Smuts JA, Baker MK, Smuts M, Stassen JMR, Rossouw E, Barnard PWA. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999;6(Suppl 4):S99-S102.
5. Relja M. Treatment of tension-type headache with botulinum toxin: 1-year follow-up. Cephalagia 2000;20:336.
6. Smuts JA, Barnard PWA. Botulinum toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalagia 2000;20:332.
7. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for the treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-76.
8. Brin MF, Swope DM, O'Brien C, Abbasi S, Pogoda JM. BOTOX for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalgia 2000;20:421-2.
9. Mauskop A, Basdeo R. Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalagia 2000;20:422.
10. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-50.
11. Knusel B, Grant M, Loesser JD, et al Intramuscular injection of botulinum toxin type A (BOTOX®) in chronic low back pain associated with muscle spasm. Poster #672, presented at the American Pain Society Meeting, San Diego, CA, November 1998.
12. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994;80:705-6.
13. Chesire WP, Abasbian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-9.
14. Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 2002;47:667-70.
15. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146-S168.
16. Silberstein S. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001;2:1649-54.
17. Dolly JO, Ashton AC, Evans D, et al. Molecular action of botulinum neurotoxins: role of acceptors in targeting to cholinergic nerves and in the inhibition of the release of several transmitters. In: Dowdall MJ, Hawthorne J, eds. Cellular and Molecular Basis of Cholinergic Function. Chichester, UK: Ellis Horwood, 1987: 517-35.
18. Sanchez-Prieto J, Sihra TS, Evans D, et al. Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes. Eur J Biochem 1987;165:675-81.
19. Ashton AC, Dolly JO. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortico synaptosomes. J Neurochem 1988;50: 1808-16.
20. Nakov R, Habermann E, Hertting G, et al. Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release. Eur J Pharmacol 1989;164:45-63.
21. McInnes C, Dolly JO. Ca2+-dependent noradrenaline release from permeabilized PC12 cells is blocked by botulinum neurotoxin A or its light chain. FEBS Lett 1990;261:323-6.
22. McMahon HT, Foran P, Dolly JO, et al. Tetanus and botulinum toxins type A and B inhibit glutamate, gamaaminobuturic acid, aspartate, and met-enkephalin release from synaptosomes. J Biol Chem 1992;267:21338-43.
23. Blasi J, Binz T, Yamasaki S, et al. Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins. J Physiol 1994;88:235-41.
24. Prukiss JR, Welch MJ, Doward S, Foster KA. Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms. Biochem Soc Trans 1997;25:542S.
25. Iskawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000;44:106-9.
26. Sala C, Andreose JS, Fumagalli G, et al. Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 1995;15:520-8.
27. Black JD, Dolly JO. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 1987;23:767-79.
28. Filippi GM, Errico P, Santarelli R, et al. Botulinum-A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113: 400-4.
29. Kaji R, Kohara N, Katayama M, et al. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 1995;18:234-5.
30. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-96.
31. Aoki R. Botulinum toxin and possible central effects. J Neurol 2001;248(Suppl 1):1/3-1/10.
32. Binder WJ, Brin MF, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 2002;48:323-35.
33. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum-Toxin A in der therapie von kopfschmerzerkrankungen und perikranialen schmerzsyndromen. Nervenarzt 2001;72:261-74.
34. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18(6 Suppl):S177-81.
35. Klein AW. Beauty, biological weapons, and Botox. Science 2002;296:468-9.
36. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis: new observations. Am J Phys Med Rehabil 1993;42:364-8.
37. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28:512-5.
38. Kagan A. Letter to the editor: re: neuralgia following herpes zoster infection. Am J Pain Manag 2002;12:43-4.
39. Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002;81: 770-5.
40. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002;81:751-9.
41. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003;84(3 Suppl 1):S69-73.
42. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002;6:460-9.
43. Verheyden J, Blitzer A. Other noncosmetic uses of BOTOX. Dis Mon 2002;48:357-66.
44. Chalkiadaki A, Rohr UP, Hefter H. Fruhe schmerzreduktion in der therapie von spastik nach einmaliger botulinustoxin-A-injektion. Dtsch Med Wochenschr 2001;126:1361-4.